Green Cross Health (GXH) H1 2025 earnings summary

Executive summary

• Group revenue rose 4% year-over-year to $259.9m for the six months ending 30 September 2024, driven by organic and acquisitive growth in Medical and strong dispensary performance in Pharmacy.

• Operating profit increased 8% to $16.1m, reflecting labour efficiencies and cost management across both divisions.

• Net profit after tax increased to $8.1m from $7.7m year-over-year.

• EPS was 3.93c, slightly up from 3.91c year-over-year.

• Interim dividend of 2.5cps declared, payable 18 December 2024.

Financial highlights

• Operating cash flow rose 38% to $25.3m, supported by improved working capital management.

• Gearing ratio at 16.9% with net debt of $5.7m and undrawn debt facilities of $32.5m as of 30 September 2024.

• Cash and cash equivalents increased to $28.9m from $18.5m year-over-year.

• Profit before tax was $11.1m, compared to $10.5m in the prior year period.

• Final dividend of 2.0cps paid in June 2024.

Outlook and guidance

• Focus remains on cost control, margin management, and leveraging technology to drive efficiencies.

• Continued investment in network expansion, technology, and omni-channel customer experience.

• Interim dividend of 2.5cps declared, fully imputed, to be paid on 18 Dec 2024.